Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial donations made in 2015 and 2016 to an independent charity patient assistance foundation that aided patients living with multiple sclerosis.

Advanced Sterilization Products (ASP) released today an interview with experts Ryan Lewis, M.D., Senior Director of Medical Affairs and Medical Safety, and Jeremy Yarwood, Vice President of Research and Development.

Innovative external urine collection device improves quality of care and reduce facility costs

Four real-world studies presented at the Annual Liver Meeting of the American Association for the Study of Liver Diseases

A large new study has found that an artery disease that mostly affects legs and feet is associated with increased use of opioids, the Society for Vascular Surgery reports.

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC) recently honored six community health centers in the U.S. with the "Innovations in Care" award in recognition of their success in low-resource areas identifying and assisting vulnerable people to better manage complex chronic diseases and improve their health.

New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.

Low-Dose Aspirin Continues to be the Gold Standard Treatment After Having a Heart Attack or Ischemic Stroke

Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve.

For Second Year, Company Will Serve as Kidney Walk National Presenting Sponsor

Several citizens and organizations commented on an increased fear of diseases stemming from pollution related to hog farming in the area at the first of two meetings held by the North Carolina Department of Environmental Quality (DEQ) on proposed changes to three general animal operations permits.

Cleveland-based startup hires new CEO and prepares for market clearance

Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, show improved progression-free survival in newly diagnosed patients

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).

Ensuring patients with heart failure have access to the latest evidence-based care, and improved outcomes and quality of life, is at the core of a hospital certification program offered by the American Heart Association, the world’s leading voluntary organization dedicated to building healthier lives, free of cardiovascular diseases and stroke, and The Joint Commission, the nation’s largest independent health care evaluation organization.

Today the American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) regarding proposals to reduce prescription drug costs outlined in the administration’s Request for Information (RFI) regarding its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (blueprint).